)
)
)
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer (SGX942), and Behçet's Disease (SGX945).
Year Founded
1987
Next catalyst (value inflection) update
HyBryte Ph 3 Interim Analysis
Expected time of next catalyst update
By June 2026
City
Princeton
Country
United States
Company CEO or top company official
Christopher J. Schaber, PhD
Development Phase of Primary Product
Phase III
Exchange
Nasdaq
Lead Product in Development
HyBryte
Therapeutic Area
Orphan/Rare Diseases
Ticker
SNGX
Website
https://www.soligenix.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
